Vaxart Receives BARDA Approval for Phase 2b Trial

Vaxart ( (VXRT) ) just unveiled an update.

On May 15, 2025, Vaxart, Inc. announced that it received approval from the Biomedical Advanced Research and Development Authority (BARDA) to begin dosing in the 10,000-participant portion of its Phase 2b clinical trial for its oral COVID-19 vaccine candidate. This trial, funded under Project NextGen, is a significant step in evaluating the efficacy and safety of Vaxart’s oral vaccine compared to existing mRNA vaccines, potentially impacting the company’s market positioning and offering a new approach to COVID-19 vaccination.

The most recent analyst rating on (VXRT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.

Spark’s Take on VXRT Stock

According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.

Vaxart’s overall score is driven by strong revenue growth and strategic initiatives, such as the proposed reverse stock split. However, profitability and cash flow issues, along with technical bearish momentum and potential NASDAQ delisting, weigh heavily on the stock. The company’s efforts to improve its financial position and operational efficiencies are crucial for future stability.

To see Spark’s full report on VXRT stock, click here.

More about Vaxart

Vaxart is a clinical-stage biotechnology company that focuses on developing oral recombinant vaccines using its proprietary delivery platform. The company’s vaccines are designed to be administered in pill form, eliminating the need for refrigeration and reducing the risk of needle-stick injuries. Vaxart’s development programs include vaccines for coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV).

Average Trading Volume: 2,009,774

Technical Sentiment Signal: Sell

Current Market Cap: $94.82M

See more insights into VXRT stock on TipRanks’ Stock Analysis page.